# Neovac 2 Burkina Faso: Impact of the Integration of Hepatitis B Birth Dose Vaccine Into the Infant Immunization Schedule

> **NCT04029454** · NA · COMPLETED · sponsor: **Institut Pasteur** · enrollment: 10000 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **BIOLOGICAL:** birth dose vaccination against hepatitis B strategy

## Key facts

- **NCT ID:** NCT04029454
- **Lead sponsor:** Institut Pasteur
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-19
- **Primary completion:** 2023-08-31
- **Final completion:** 2023-12-15
- **Target enrollment:** 10000 (ACTUAL)
- **Last updated:** 2023-12-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04029454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04029454, "Neovac 2 Burkina Faso: Impact of the Integration of Hepatitis B Birth Dose Vaccine Into the Infant Immunization Schedule". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04029454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*